Home › Research › Prevention and risk
Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial
Crivelli L, Suemoto CK, Sosa AL, Lopera F, Aguillón D, Allegri RF, Nitrini R, Calandri IL, Velilla-Jiménez L, Yassuda MS, et al.. The Lancet, 2026-07-13
Topic: Risk, prevention and care in population studies
Background Latin America faces a high dementia burden, with increased prevalence of factors associated with cognitive decline. Recruitment effectiveness (Reach) was 62·0%; mean adherence to the SLI group (Implementation) was 71·6% over the entire trial; and frequencies of complete cognitive outcomes data (Maintenance) were 87·9% at 6 months, 85·3% at 12 months, 81·4% at 18 months, and 84·8% at 24 months in the SLI group compared with 86·3% at 6 months, 78·9% at 12 months, 73·4% at 18 months, and 79·8% at 24 months in the FLI group. These findings extend the evidence base for multidomain lifestyle interventions to populations historically under-represented in dementia research, supporting their feasibility and scalability as strategies to reduce cognitive decline risk amid the rapidly growing burden of dementia in low-income and middle-income countries.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Crivelli, L., Suemoto, C. K., Sosa, A. L., Lopera, F., Aguillón, D., Allegri, R. F., et al. (2026). Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial. The Lancet. https://doi.org/10.1016/S0140-6736(26)01278-X
Vancouver
Crivelli L, Suemoto CK, Sosa AL, Lopera F, Aguillón D, Allegri RF, et al. Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial. The Lancet. 2026. doi:10.1016/S0140-6736(26)01278-X. PMID: 42442374.
BibTeX
@article{crivelli2026-42442374,
author = {Crivelli, L. and Suemoto, C. K. and Sosa, A. L. and Lopera, F. and Aguillón, D. and Allegri, R. F. and Nitrini, R. and Calandri, I. L. and Velilla-Jiménez, L. and Yassuda, M. S. and others},
title = {{Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial}},
journal = {The Lancet},
year = {2026},
doi = {10.1016/S0140-6736(26)01278-X},
pmid = {42442374},
url = {https://doi.org/10.1016/S0140-6736(26)01278-X}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Background Latin America faces a high dementia burden, with increased prevalence of factors associated with cognitive decline.
- Recruitment effectiveness (Reach) was 62·0%; mean adherence to the SLI group (Implementation) was 71·6% over the entire trial; and frequencies of complete cognitive outcomes data (Maintenance) were 87·9% at 6 months, 85·3% at 12 months, 81·4% at 18 months, and 84·8% at 24 months in the SLI group compared with 86·3% at 6 months, 78·9% at 12 months, 73·4% at 18 months, and 79·8% at 24 months in the FLI group.
- These findings extend the evidence base for multidomain lifestyle interventions to populations historically under-represented in dementia research, supporting their feasibility and scalability as strategies to reduce cognitive decline risk amid the rapidly growing burden of dementia in low-income and middle-income countries.
Why it matters
This trial in Latin America tested a multidomain lifestyle intervention in older adults at risk of cognitive decline and reported on how well the program was delivered and how many participants stayed in it. It supports the feasibility of such programs in populations historically under-represented in dementia research, but the text does not report whether the intervention reduced cognitive decline.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designRCT
- Participants1,065
- Effect sizeBetween-group difference in global cognitive composite 0.11 SD per year (95% CI 0.06-0.15)
- Evidence strengthModerate
Limitations
Both groups improved, consistent with practice effects; participants and staff unmasked; the control received an active advice intervention rather than nothing; cognitive scores rather than dementia diagnoses were the outcome.
How this study scored 72/100
Published in a top-tier journal, and it is a randomised controlled trial. We have no data on free to read, so that was left out: it earned 71 of the 98 points we could judge it on, which is 72 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (The Lancet) |
| Journal's citation record | 4 / 4 | The Lancet: journal h-index 1,205 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomised controlled trial |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,065 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 2 / 2 | Randomised and blinded or placebo-controlled (as stated in the record) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 4 / 6 | Cited 14.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Gustavo Emilio Sevlever: h-index 34 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Southern California: institution h-index 1,521 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 36 institution(s) in 14 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42442374) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 71 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 71 of the 98 points we could judge it on is 72 out of 100. |
| Total | 72 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Prevention and risk
Also tagged “controlled”
1,116 studies in the library carry the topic tag “controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,116 tagged studies.